Amgen Inc (AMGN) 151.65 $AMGN No Easy Cure for What Ails

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2015 at 12:49 PM

Amgen Inc (AMGN) 151.65 $AMGN

No Easy Cure for What Ails Biotech Stocks
at The Street - 1 hr 19 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 277.35 (+1.01), VRX: 101.34 (-17.27), GILD: 102.02 (+0.29), MYL: 38.97 (-1.92), AMGN: 151.65 (+1.56)

Stock Market News for October 22, 2015
Zacks Equity Research - Zacks Investment Research - 2 hrs 39 mins ago
Benchmarks ended Wednesday’s volatile trading session in the red following declines in healthcare and energy shares
KO: 43.80 (+1.61), KMI: 29.98 (-1.44), VRX: 101.34 (-17.27), MDT: 73.50 (+0.08), PFE: 33.13 (-0.33), UNH: 111.63 (-6.48), AMGN: 151.65 (+1.56), XOM: 82.22 (+2.01), COP: 54.30 (+1.33), BMY: 62.85 (+0.34), BA: 146.85 (+5.66), YHOO: 31.85 (+0.73), GM: 35.39 (-0.03), CVX: 91.37 (+2.04), OXY: 74.02 (+2.01)

Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN.
ABT: 42.78 (+0.58), CMG: 660.45 (-5.22), HZNP: 13.63 (-1.20), AMGN: 151.65 (+1.56), BAC: 16.17 (+0.27)

The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
HD: 123.73 (+0.43), NKE: 131.38 (-1.09), AMGN: 151.65 (+1.56), MO: 61.19 (+1.35), AAPL: 115.00 (+1.24)

Go Back to the Future with These 5 Market Crushing Stocks
Eric Dutram - Zacks Investment Research - Wed Oct 21, 3:55PM CDT
If you ever have a time machine that can go back to 1985, you better buy these top performing stocks which have crushed the market over the past 30 years.
HD: 123.73 (+0.43), NKE: 131.38 (-1.09), AMGN: 151.65 (+1.56), MO: 61.19 (+1.35), AAPL: 115.00 (+1.24)

Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:35PM CDT
Kite Pharma (KITE) looks set to gain orphan drug status for KTE-C19 in the EU for three additional blood cancer indications.
BLUE: 80.30 (-0.48), KITE: 68.57 (+1.42), AMGN: 151.65 (+1.56), JUNO: 49.20 (+2.51)

Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
PR Newswire - Wed Oct 21, 3:15PM CDT
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program's alignment with the United States' Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
AMGN: 151.65 (+1.56)

Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 277.35 (+1.01), AMGN: 151.65 (+1.56), AEGR: 15.32 (+0.34)

Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 8:15AM CDT
Illumina's (ILMN) bottom line comfortably exceeded the Zacks Consensus Estimate, while the top line came in line with the same
AMGN: 151.65 (+1.56), ILMN: 141.33 (+1.16), ANIK: 33.96 (-0.32), NVET: 3.89 (+0.10)

New Tech Partnership Aims for Faster Rape Kit Processing
ACCESSWIRE - Tue Oct 20, 8:14AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 20, 2015 / Pressure BioSciences Inc. (OTCQB: PBIO), a developer and marketer of proprietary laboratory instrumentation and associated consumables to the $6 billion life sciences sample preparation market, aims to develop a rape kit test method based on its patented PCT Platform and launch it commercially within the next 18 months. With the potential to significantly speed up rape kit testing, the technology could help fill an enormous unmet need in the United States.
ENZ: 3.83 (+0.09), TMO: 126.43 (-0.68), NEO: 7.00 (-0.08), AMGN: 151.65 (+1.56)

Will Tecfidera Slowdown Hit Biogen (BIIB) Earnings in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 5:47PM CDT
Will Biogen (BIIB) miss third quarter expectations due to the slowdown in Tecfidera sales?
BIIB: 277.35 (+1.01), AMGN: 151.65 (+1.56), TEVA: 55.99 (-1.93)

After Yesterday's Rally of 1.22% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 151.65 (+1.56)

Watch for Amgen to Potentially Pullback After Gaining 1.22% Yesterday
Comtex SmarTrend(R) - Mon Oct 19, 3:57PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $152.46 to a high of $156.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $154.12 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 151.65 (+1.56)

Is Lilly (LLY) Poised to Beat Earnings Expectations in Q3?
Arpita Dutt - Zacks Investment Research - Mon Oct 19, 3:26PM CDT
Will Lilly (LLY) succeed in surpassing earnings expectations on the back of strong diabetes and animal health segment sales?
AMGN: 151.65 (+1.56), LLY: 76.81 (-0.20), NVS: 92.22 (+0.63)

Zafgen Continues to Fall; Partial Clinical Hold on Beloranib
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 3:25PM CDT
Zafgen, Inc. (ZFGN) fell 50.7% after the company received a verbal notice from the FDA stating that beloranib has been placed on partial clinical hold.
ZFGN: 11.20 (+0.48), AMGN: 151.65 (+1.56), BMY: 62.85 (+0.34), ANIK: 33.96 (-0.32)

What's in Store for Morningstar (MORN) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 2:35PM CDT
Morningstar Inc. (MORN) is set to report third-quarter 2015 results on Oct 21.
SKYW: 19.57 (+0.30), AMGN: 151.65 (+1.56), MORN: 82.62 (+0.64), ANIK: 33.96 (-0.32)

Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 1:50PM CDT
Abbott Laboratories (ABT) carrying a Zacks Rank #4 and an Earnings ESP of -1.83% is scheduled to report third-quarter 2015 results on Oct 21, 2015.
ABT: 42.78 (+0.58), AMGN: 151.65 (+1.56), LLY: 76.81 (-0.20), BMY: 62.85 (+0.34)

Will Hubbell (HUB- Disappoint Earnings Estimates in Q3?
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 12:25PM CDT
Hubbell Inc. (HUB- is set to report third-quarter 2015 results on Oct 22.
SKYW: 19.57 (+0.30), AMGN: 151.65 (+1.56), ANIK: 33.96 (-0.32), HUB.B: 92.55 (+5.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Volkswagen Leasing's MXN 2.5B Move Through Bolsa

Reading the Fine Print in VW Leasing's Latest Move Let's get right into the weeds: Volkswagen Leasing's cranking out MXN 2.5 billion in long-term debt certificates. This maneuver ain't happening in a vacuum—it's powered by the intricate levers behind Greenberg Traurig's sharp legal mind. This isn't just another financial transaction; it's a strategically framed...

Jackson Hewitt Aims to Recruit 15,000 Seasonal Staff

Revving Up for Tax Season: Jackson Hewitt's Hiring Push When tax season looms, the hustle can't be understated, and Jackson Hewitt is cranking it up by hunting for 15,000 new recruits to tackle this annual financial circus. Starting October 26, this hiring fest is open season across the nation, pulling out all the stops to bolster its workforce. But what does this mean...

Kat Florence Hotels Offers Unique $20K Wine Tastings

Luxury Retreat Offering Free Rare Wine Tastings The world of high-end hospitality just got a bit more intoxicating, literally. As of October 20, guests at the Elora luxury retreat, part of the Kat Florence Hotels portfolio, can indulge in some of the most coveted wines on the planet—gratis. That's right, wine aficionados can thank Kat Florence's latest extravagant...

King City Gardens Debuts Third Dispensary in Cincinnati

Every corner of Cincinnati’s cannabis scene just got a little busier with King City Gardens opening up shop in Colerain Township. This move marks their third Garden Dispensary in Greater Cincinnati. It’s not just about adding another location, though. It’s King City’s way of cementing their local roots deeper into the city’s soil, rolling out a mix of...

Norwegian Bella™: A New Era in Luxury Cruising

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

Prosecco DOC Chef Residency Debriefs on Inaugural Year

A Fusion of Flavors: The Residency Recap Alright, listen up. The Prosecco DOC Chef Residency has wrapped its initial bash in Italy, where it played culinary matchmaker with talents from Brazil, South Korea, Canada, and the UK. Picture some top-notch chefs crossing borders and tweaking recipes with that unique Italian spark of Prosecco DOC. It wasn't just some ballroom...

NCD Debuts Tool for Medicare Advantage Dental Plans

NCD Takes a Stab at Simplifying Medicare Advantage Dental Plans Alright, let's cut through the clutter and get to what's what. NCD has rolled out a new tool for Medicare Advantage plans, specifically targeting the dental benefits part. This isn't just a fancy gadget, but a real tool built from CMS data to provide some clarity in the chaotic world of health plans. We've...

Freight Rebound Sparks Strategic M&A Opportunities

Is the Freight Recovery Here to Stay? Just when you thought trucking might have run out of gas, we're hitting a sharp turn back into growth town. For those of you dropping equity crumbs every which way but loose in the last few years, this freight lull has been brutal—like the hangover from hell. But Brown Gibbons Lang & Company’s fresh report now hints at a brighter...

ARPwave Therapy: A Game Changer For Patient Recovery

New Insights in Recovery with ARPwave Therapy Getting stuck in a rehab rut is not uncommon. That's where ARPwave therapy steps in, taking an innovative approach to healing by focusing on the nervous system's role in recovery. Props to Jeff Kessler from Maximum Health Physical Therapy for shedding light on this game-changing method during an insightful piece in...

Laredo Oil Eyes Big Gains in Argentina's Oil Play

Argentina's Oil Play: Laredo Oil's Bold Venture Talk about shooting for the stars. Laredo Oil's second tête-à-tête with Santa Cruz Province's big wigs highlights their itch to rejuvenate Argentina's tired oil fields. For folks who know the nitty-gritty of oil, we're talking about the Golfo San Jorge Basin, a place where old dogs might learn new tricks thanks to that...